Bone Biologics Corporation

AI-generated fair value estimate for this company.

Method: Net asset value (cash-based) approach for a pre-revenue clinical-stage medtech: total stockholders' equity of $4.67M (almost entirely the $4.53M cash balance) divided by 2.76M shares outstanding = $1.69/share.

Reasoning: Bone Biologics has no revenue and a ~$2.89M/yr cash burn, so a DCF is not meaningful; the balance-sheet cash position (funding roughly 19 months of runway) is the most defensible value anchor. The stock's $1.31M market cap trading well below its $4.67M net-cash-heavy equity implies the market is pricing in near-term dilution/going-concern risk beyond the cash balance itself.